Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTX-022 in Pachyonychia Congenita
NCT03920228Phase 3Completed
- Sponsor
- Palvella Therapeutics
- Start
- Apr 2019
- Primary completion
- Sep 2020
- Modality
- Polymer-based Nanoparticles, Transdermal Patches, Hydrogel Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of QTORIN rapamycin in pachyonychia congenita (PC) (4 arms), sponsored by Palvella Therapeutics. Primary endpoint: Patient Global Assessment of Activities Scale at 6 months. Started Apr 2019; status: completed.
02
Drugs
QTORIN rapamycin
03
Conditions
pachyonychia congenita (PC)
Beyond the preview
Go deeper on NCT03920228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03920228.